<DOC>
	<DOCNO>NCT01625377</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy early introduction one month post-transplantation everolimus associate EC-MPS tacrolimus discontinuation de novo liver transplant recipient evaluate lead well renal function 6 month post-transplantation compare standard treatment associate tacrolimus EC-MPS . The renal function estimate glomerular filtration rate .</brief_summary>
	<brief_title>A National Multi-center Randomized , Open Label Study Evaluate Efficacy Safety Everolimus With EC-MPS Compared Standard Treatment Combination Tacrolimus EC-MPS de Novo Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Man woman age 18 year great , recipient primary liver transplant decease donor whole split liver Key Patient recipient multiple solid organ islet cell tissue transplant , previously receive organ tissue transplant Recipient liver live donor cadaveric non heart beat donor ABO incompatible transplant graft Transplantation follow autoimmune liver hepatitis , primitive sclerosing cholangitis primitive biliary cirrhosis Estimated glomerular filtration rate â‰¤ 30ml/min selection History malignancy within 5 past year , nonmetastatic basal squamous cell carcinoma hepatocellular carcinoma Alphafoetoprotein &gt; 1000 ng/ml ( case hepatocellular carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Everolimus ,</keyword>
	<keyword>liver transplantation ,</keyword>
	<keyword>early introduction ,</keyword>
	<keyword>renal function</keyword>
</DOC>